Canopy Growth 3Q 2026: Revenue C$99.51M, EPS (C$0.1) — 10-Q Summary
Canopy Growth reported fiscal Q2 revenue of C$99.51M, up 20% YoY, but net loss widened to C$40.69M. Growth in cannabis sales, particularly international and Canadian adult-use, was offset by lower Storz & Bickel sales and higher expenses. Adjusted EBITDA loss narrowed slightly to C$2.9M.
How this was made

The 30-second read
Why it matters
The earnings release provides fresh data on revenue growth versus loss expansion, influencing short‑term price action.
Market read
The earnings miss is likely to trigger a near‑term sell‑off in CGC and may affect sentiment across the cannabis sector.
What to watch
International market expansion and medical cannabis reimbursement changes may offer upside beyond the headline loss.
Background
The article is an AI‑generated summary of Canopy Growth's 10‑Q filing for fiscal Q2 2026.
Ticker impact
Canopy Growth reported Q2 revenue of C$99.51M and a widened net loss in its 10‑Q filing.
downward pressure as investors price in the widened loss and higher expenses
The company posted a 20% revenue increase but a 717% loss expansion, which typically triggers a sell‑off.
Market effects
Cannabis sector may see broader pressure as a major player reports a widening loss.
Canadian cannabis market sentiment could soften following the results.
Limited; primarily affects investors focused on North American cannabis stocks.
Counterpoint
Despite the loss, revenue growth and margin improvement in Storz & Bickel could support a longer‑term rebound.
Key entities
- companyCanopy Growth Corp
Canadian cannabis producer listed on the NYSE under CGC.



